MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial
MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement to raise approximately $695,000.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Solas Capital Management Frederick Tucker Golden | 4,297,004 | $6,015,806 | 3.46% | |
| 2. | Alyeska Investment Group Anand Parekh | 2,500,000 | $3,500,000 | 0.01% | |
| 3. | 683 Capital Partners Ari Zweiman | 1,066,666 | $1,493,332 | 0.08% | |
| 4. | Corsair Capital Management Jay Petschek And Steven Major | 100,000 | $140,000 | 0.02% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.39 | 72,700 | $100,885.79 | 976,121 | 2026-06-01 | Filing | |
| $1.34 | 75,000 | $100,200.00 | 1,519,178 | 2026-06-01 | Filing | |
| $1.35 | 2,000 | $2,690.00 | 46,511 | 2026-06-01 | Filing | |
| $3.69 | 2,700 | $9,958.68 | 1,424,178 | 2022-09-19 | Filing | |
| $1.22 | 57,189 | $69,999.34 | 1,421,478 | 2025-12-22 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 34,135 | $49,154 | 0.03% |